Funakoshi, Takeru

写真a

Affiliation

School of Medicine, Department of Dermatology ( Shinanomachi )

Position

Associate Professor

External Links
Scopus Paper Info  
Paper Count: 123 Citation Count: 2241 h-index: 25

Click to view the Scopus page. The data was downloaded from Scopus API in March 29, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲

Profile 【 Display / hide 】

  • 電子顕微鏡による微細構造解析、皮膚病理学を研究テーマとしていた。その後、天疱瘡における自己抗体サブクラス解析を経て、皮膚がん領域の研究活動に従事するようになる。現在は、主に介入型の医師主導臨床試験の計画と実施を主たる研究テーマとし、日々の診療と並行して研究を遂行している。

Page Top ▲

Career 【 Display / hide 】

  • 2009.08
    -
    2010.07

    University of Pennsylvania, Department of Dermatology, Visiting Scholar

  • 2010.08
    -
    2014.09

    Keio University School of Medicine, Department of Dermatology, 助教

  • 2014.10
    -
    2022.03

    Keio University School of Medicine, Department of Dermatology, Assistant Professor

  • 2022.04
    -
    Present

    Keio University School of Medicine, Department of Dermatology, Associate Professor

Page Top ▲

Academic Background 【 Display / hide 】

  • 1995.04
    -
    2001.03

    Keio University, School of Medicine

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, Keio University, Dissertation

Page Top ▲

Matters concerning Career Achievements 【 Display / hide 】

  • 2015.06

    慶應義塾大学プレスリリース「創傷部にメラノーマ（ほくろのがん）が転移するしくみを解明　創傷が治癒する際に生じるペリオスチンが原因」

  • 2023.06

    慶應義塾大学プレスリリース「根治切除不能な進行・再発の上皮系皮膚悪性腫瘍に対する 抗PD-1抗体療法の有効性を医師主導治験で示す－オプジーボ®点滴静注の国内製造販売承認事項の一部変更承認申請へ－」

  • 2024.02

    慶應義塾大学プレスリリース「根治切除不能な進行・再発の上皮系皮膚悪性腫瘍に対する抗PD-1抗体療法の有効性を医師主導治験で示す－オプジーボ®点滴静注の国内製造販売承認事項の一部変更承認を取得－」

  • 2024.07

    慶應義塾大学プレスリリース「外陰部皮膚がんの薬剤耐性の仕組みを解明－治療開発への貢献に期待－」

  • 2024.08

    慶應義塾大学プレスリリース「標準治療が確立されていなかった進行期乳房外パジェット病を対象とする内分泌療法の医師主導治験を国内7施設で開始」

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Dermatology

Page Top ▲

Research Keywords 【 Display / hide 】

  • Skin cancer

Page Top ▲

Research Themes 【 Display / hide 】

  • Clinical Trial on Skin Cancer, 

    2010.08
    -
    Present

Page Top ▲
 

Books 【 Display / hide 】

  • 皮膚科のくすりの使い方

    舩越建, じほう, 2019.08

    Scope: 悪性腫瘍（メラノーマ）,  Contact page： 218-222

  • マイナー外科救急レジデントマニュアル

    Funakoshi Takeru, 医学書院, 2016.07

    Scope: 262-298

Page Top ▲

Papers 【 Display / hide 】

  • Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors

    Saito Y., Horie S., Kogure Y., Mizuno K., Ito Y., Mizukami Y., Kim H., Tamura Z., Koya J., Funakoshi T., Hirata K., Kataoka K.

    Nature Medicine 32 ( 2 ) 690 - 701 2026.02

    ISSN  10788956

    　View Summary

    Comprehensive genomic profiling (CGP) is crucial in precision oncology, yet its real-world utility remains unclear. Here we analyzed data from the Japanese nationwide Center for Cancer Genomics and Advanced Therapeutics database, including clinical and genetic data from 54,185 patients with advanced solid tumors (consisting of 81 common and rare tumor types) who received CGP with a targeted sequencing panel covering 324 genes as part of their clinical care. We assessed the prognostic value of CGP-guided clinical evidence-level classification, showing that alterations predicting response to Pharmaceuticals and Medical Devices Agency-approved or Food and Drug Administration-approved therapies and to therapies supported by well-powered studies with expert consensus are detected in 16.6% and 8.1% of patients, respectively, and are associated with better prognosis than those with lower clinical evidence levels. Only 8% of patients receive CGP-guided approved–experimental genomic biomarker-linked therapies, although the proportion has improved over time. Substantial differences were observed across tumor types, with the proportions exceeding 20% in thyroid and lung cancers but remaining below 2% in pancreatic and liver cancers. Tumor-agnostic biomarker analyses reveal that tumor mutational burden (TMB) ≥20 mutations per megabase predicts better outcome across tumor types, regardless of microsatellite instability status, in TMB-high patients receiving pembrolizumab. Conversely, extramammary Pagetʼs disease is exceptionally resistant to pembrolizumab. The large-scale nationwide database allows evaluating inter-tumor type differences and investigating evidence-scarce situations, delineating where CGP offers greater benefit. These real-world findings complement those from clinical trials and prospective sequencing projects regarding CGP, providing valuable information for individualized treatment.

  • A case of disseminated and chronic varicella zoster virus infection with persistent ulcer formation in a rheumatoid vasculitis patient treated with immunosuppressants

    Kakuta R., Nakamura Y., Kobayashi K., Sawada K., Uchikawa R., Watanuki S., Tanese K., Imai Y., Kaneko Y., Funakoshi T.

    Jaad Case Reports 65   153 - 156 2025.11

  • Prognosis of a deep excision margin within or beyond subcutaneous fat for invasive acral melanoma of the sole: A multi-institutional retrospective study

    Koizumi S., Yamazaki N., Ichigozaki Y., Kitagawa H., Kiniwa Y., Sato S., Takai T., Doi R., Ito T., Yasuda M., Kuwatsuka Y., Maekawa T., Asai J., Miyagawa T., Matsushita S., Funakoshi T., Yamamoto Y., Inozume T., Kishi A., Takenouchi T., Kokubu H., Ito S., Umeda Y., Yamamoto Y., Ishizuki S., Iino S., Uchi H., Nakagawa T., Inafuku K., Haga T., Kaneko T., Nakagawa M., Arima M., Hoashi T., Hiura A., Nagai M., Manabe K., Ishikawa M., Asagoe K., Iwasawa U., Kadono T., Hatta N., Minami S., Nakano E., Ogata D., Fukushima S., Uhara H., Nakama K., Nakamura Y.

    Surgery United States 186 2025.10

    ISSN  00396060

    　View Summary

    Background: Preservation of plantar subcutaneous fat is crucial for cushioning in the surgical treatment of acral melanoma of the sole. However, no studies exist on the relationship between deep margins and prognosis. We aimed to retrospectively compare the prognoses of different deep margins (within or beyond the subcutaneous fat) in patients with invasive acral melanoma of the sole who underwent wide local excision. Methods: In this multi-institutional retrospective study, survival was compared between 2 groups of patients: those with tumors excised within (S group) and those beyond the subcutaneous fat (D group). Results: In total, 464 patients were included. Cox multivariable analyses showed that the depth of the deep excision margin was not associated with local recurrence–free survival, overall survival, or distant metastasis–free survival (hazard ratios of 1.20, P = .36; 1.10, P = .66; and 1.42, P = .05, respectively). However, excision beyond the subcutaneous fat was negatively associated with disease-free survival (hazard ratio 1.45, P = .02). After propensity score matching (both groups, n = 139), no significant differences were observed in survival outcomes between the S and D groups (5-year local recurrence-free survival: 72.8 vs 66.8%, P = .55; 5-year disease-free survival: 55.3 vs 43.7%, P = .24; 5-year overall survival: 76.2 vs 73.2%, P = .52; 5-year distant metastasis–free survival: 63.3 vs 54.1%, P = .13). Subgroup analysis of American Joint Committee on Cancer stages revealed no significant differences in survival outcomes between the 2 groups at any stage. Conclusion: Wide local excision beyond the subcutaneous fat was not associated with survival benefit of acral melanoma of the sole. Excision within the subcutaneous fat may represent the optimal deep margin.

  • Effectiveness and Prognosis of Systemic Chemotherapy for Unresectable Malignant Apocrine and Eccrine Tumors: A Real-World Multicenter Retrospective Study

    Saito S., Yasuda M., Araki T., Ogata D., Onishi M., Yoshikawa S., Inaba Y., Okada E., Kato J., Takenouchi T., Fujisawa Y., Irie H., Kiniwa Y., Yamamura S., Isei T., Konno T., Muto I., Yamamoto Y., Maekawa T., Tanaka R., Omine T., Asai J., Iino S., Nakamura M., Nakamura Y., Nagase K., Kato T., Kuwatsuka Y., Funakoshi T., Motegi S.I.

    JCO Global Oncology 11 2025.09

    　View Summary

    PURPOSE: Malignant apocrine and eccrine tumors (MAETs) are extremely rare cutaneous adnexal malignancies, accounting for only 0.005%-0.01% of all skin tumors. These tumors are highly metastatic, and evidence regarding optimal chemotherapy and prognostic outcomes remains limited. This study aimed to evaluate the efficacy of systemic chemotherapy and overall prognosis in Japanese patients with unresectable MAETs. PATIENTS AND METHODS: We conducted a retrospective, multicenter study involving 81 patients with unresectable MAETs treated at 27 institutions across Japan. Patients received one of three primary chemotherapy regimens: platinum-based (cisplatin or carboplatin), taxane-based (docetaxel or paclitaxel), or TS-1 (tegafur/gimeracil/oteracil). Patient demographics, objective response rates (ORRs), overall survival (OS), and progression-free survival were assessed. Survival curves were estimated using the Kaplan-Meier method. RESULTS: The estimated ORRs for the platinum-based, taxane-based, and TS-1 groups were 37.0%, 25.0%, and 22.2%, respectively, with no statistically significant differences among them (P = .527). The median OS and 5-year OS rate for the entire cohort were 29.0 months and 34.0%, respectively. The median OS and 5-year OS rates by regimen were as follows: platinum-based, 29.0 months and 36.2%; taxane-based, 22.0 months and 39.7%; and TS-1, 30.0 months and 13.9%, with no significant differences observed (P = .907). In addition, there were no significant differences in ORR or OS between patients receiving combined chemoradiotherapy and those receiving chemotherapy alone. CONCLUSION: No single chemotherapeutic regimen demonstrated superior efficacy in patients with unresectable MAETs. These findings highlight the need for further investigations using larger, prospective cohorts and multidisciplinary approaches to establish optimal therapeutic strategies for this rare malignancy.

  • Comparing 2 cm vs. 1 cm surgical margins in acral melanoma of the sole with Breslow thickness greater than 2 mm: A multicenter retrospective study of 336 Japanese patients

    Koizumi S., Yamazaki N., Ichigozaki Y., Kitagawa H., Kiniwa Y., Sato S., Takai T., Doi R., Ito T., Yasuda M., Kuwatsuka Y., Maekawa T., Asai J., Miyagawa T., Matsushita S., Funakoshi T., Yamamoto Y., Inozume T., Kishi A., Takenouchi T., Kokubu H., Ito S., Nakamura Y.

    European Journal of Surgical Oncology 51 ( 9 )  2025.09

    ISSN  07487983

    　View Summary

    Introduction: Multiple randomized trials comparing wide local excision (WLE) with different peripheral margins have established recommended peripheral margins according to Breslow thickness (BT) in the National Comprehensive Cancer Network (NCCN) Guidelines. However, these clinical trials included only a small number of patients with acral melanoma (AM). Therefore, we aimed to compare the prognosis of different WLE peripheral margin cohorts with invasive sole AM. Materials and methods: We conducted a multi-institutional retrospective study of patients with sole AM and a BT greater than 2 mm. Survival outcomes were compared between two groups: those excised with a peripheral margin of 2 cm, as recommended by the NCCN Guidelines, and those excised with a peripheral margin of 1 cm. Results: This study included 336 patients (2 cm margin: n = 226; 1 cm margin, n = 110) with a median follow-up period of 43.1 months. In multivariate analyses, a peripheral margin of 1 cm did not negatively affect survival (local recurrence-free survival [LRFS]: hazard ratio [HR] 1.19, P = 0.38; disease-free survival [DFS]: HR 1.05, P = 0.75). Survival after propensity score matching showed no significant differences between the matched groups (each group: n = 103; 5-year LRFS: 70.6 % vs. 59.3 %, P = 0.13; 5-year DFS: 47.4 % vs. 54.0 %, P = 0.63). Conclusion: A peripheral margin of 1 cm did not negatively influence the prognosis of patients with a sole AM and a BT greater than 2 mm. Narrower surgical margins may be acceptable to minimize morbidity without compromising survival.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 造影CTで活動性出血の所見なく、血腫除去時に判明したdeep dissecting hemtomaの1例

    小川夕貴, 伏間江貴之, 舩越建, 加藤達也, 岡部圭介, 小林秀, 天谷雅行, 山上淳

    第889回日本皮膚科学会東京地方会（城西地区） (東京) , 

    2020.02

  • 薬疹　経過中に自己抗体が出現した薬剤性過敏症症候群および疑い例の検討

    椎谷千尋, 大内健嗣, 舩越建, 天谷雅行, 高橋勇人

    第49回日本皮膚免疫アレルギー学会総会学術大会 (横浜) , 

    2019.11

  • 陰圧閉鎖療法が分層植皮固定に有用であった外陰部乳房外Paget病(EMPD)の１例

    及川紗由香, 新川宏樹, 平井郁子, 中村善雄, 大内健嗣, 舩越建

    第886回日本皮膚科学会東京地方会（城西地区） (東京) , 

    2019.10

  • 激しい腹痛と肝機能障害を伴い重症化した内臓播種性水痘ウィルス感染症の1例

    野澤優, 朝倉涼平, 山上淳, 天谷雅行, 舩越建

    第886回日本皮膚科学会東京地方会（城西地区） (東京) , 

    2019.10

  • 免疫チェックポイント阻害薬治療中に発症したが、投与を継続した水疱性類天疱瘡の1例

    新谷悠花, 齋藤京, 長谷衣佐乃, 舩越建

    第886回日本皮膚科学会東京地方会（城西地区） (東京) , 

    2019.10

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 乳房外パジェット病の腫瘍微小環境および遺伝子異常を基盤とした病態機構の解明と制御

    2024.04
    -
    2027.03

    基盤研究(B), Principal investigator

  • ［再生医療実用化研究事業］ 進行性の悪性黒色腫および子宮頸癌に対する腫瘍浸潤Tリンパ球輸注療法

    2018.04
    -
    2021.03

    国立研究開発法人日本医療研究開発機構, 再生医療実用化研究事業, Yutaka Kawakami, Coinvestigator(s)

  • ［難治性疾患等実用化研究事業　難治性疾患実用化研究事業］ ステロイド治療抵抗性の天疱瘡患者を対象としたリツキシマブの医師主導治験

    2017.04
    -
    2020.03

    国立研究開発法人日本医療研究開発機構, 日本医療研究開発機構研究費, Masayuki Amagai, Coinvestigator(s)

  • ［臨床研究・治験推進研究事業］ 進行期乳房外パジェット病に対するトラスツズマブ、ドセタキセル併用療法の第II相臨床試験

    2017.04
    -
    2020.03

    国立研究開発法人日本医療研究開発機構, 臨床研究・治験推進研究事業, Principal investigator

  • ［革新的がん医療実用化研究事業］ 進行期悪性黒色腫(末端黒子型)に対する非骨髄破壊性前処置併用での腫瘍浸潤Tリンパ球輸注療法の安全性試験

    2015
    -
    2017

    AMED（国立研究開発法人日本医療研究開発機構）, No Setting

display all >>

Page Top ▲

Works 【 Display / hide 】

  • 日経産業新聞「免疫細胞、体外培養し投与、慶大が臨床試験、メラノーマ対象。」

    舩越建

    2016.09
    , 

    Other

  • 日経産業新聞「メラノーマの転移 解明」

    福田桂太郎, 舩越建, 天谷雅行

    2015.06
    , 

    Other

  • 週刊エコノミスト「＋健康アプリ：72皮膚がん」

    舩越建

    2014.02
    , 

    Other

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • CLINICAL CLERKSHIP IN DERMATOLOGY

    2025

  • PATHOPHYSIOLOGY AND CLINICAL ASSESSMENT

    2025

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2025

  • MEDICAL ONCOLOGY

    2025

  • LECTURE SERIES, DERMATOLOGY

    2025

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • 皮膚科学

    学校法人慶應義塾大学

    2018.04
    -
    2019.03

  • Dermatology

    Keio University

    2017.04
    -
    2018.03

  • 皮膚科学講義「真皮、皮下脂肪組織の疾患」「代謝異常症」2016/11/24

    Keio University

    2016.04
    -
    2017.03

  • 皮膚科学講義「真皮、皮下脂肪組織の疾患」「代謝異常症」2015/11/19　　　　　

    Keio University

    2015.04
    -
    2016.03

  • 皮膚科学講義「真皮、皮下脂肪組織の疾患」2013/11/25

    Keio University

    2013.04
    -
    2014.03

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • Japanese Dermatological Association, 

    2001
    -
    Present
Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2017.04
    -
    Present

    乳房外パジェット病ガイドライン作成委員, 乳房外パジェット病ガイドライン作成委員会

Page Top ▲